SAN FRANCISCO, Oct. 26 /PRNewswire/ -- MedImmune, Inc. today announced it will present three abstracts at the American Academy of Pediatrics (AAP) 2007 National Conference & Exhibition, adding to the company's growing body of research into the prevention of respiratory syncytial virus (RSV), a leading cause of hospitalization among infants.
"MedImmune is pleased to present data that provide key insights into how we can optimize the fight against RSV," said Jessie R. Groothuis, M.D., vice president, medical and scientific affairs, infectious disease. "Cost- effectiveness data help insurers, governments, and families understand the benefits of RSV prophylaxis and the potential impact of not taking preventive measures. Surveillance data help us understand local variants in RSV outbreaks, which can inform and improve RSV prevention guidelines."
MedImmune abstracts to be presented at AAP include:
-- Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis with
Palivizumab Among Preterm Infants After Valuing a Reduction in
Persistent Wheezing (Poster #P14) - Mark J. Polak, M.D., Saturday,
October 27th, 2007 from 12:15 - 1:00 p.m.
BACKGROUND: Recent trials have suggested that Synagis(R) (palivizumab),
a monoclonal antibody (MAb) that is the standard of care in RSV
prevention, reduced the incidence of persistent wheezing in studied
populations. Researchers conducted a cost-effectiveness analysis of
prophylaxis with Synagis compared with no prophylaxis among preterm
infants less than 32 weeks and between 32 and 35 weeks gestation,
factoring in the quality of life associated with a reduction in
-- A Nationwide Hospital RSV Surveillance Program: Interim Assessment of
the 2006-2007 RSV Season (Poster #P25) - Marnie L. Boron, PharmD,
Saturday, October 27th, 2007 from 12:15 - 1:00 p.m.
|SOURCE MedImmune, Inc.|
Copyright©2007 PR Newswire.
All rights reserved